Skip to the essay

Patient notes · November 2026

GLP-1 Journey

What the weeks feel like, from appetite to maintenance. No invented patient stories.

Note

When GLP-1 weight loss plateaus

A plateau is a stretch of time when weight, which had been falling, holds roughly still. It is not one noisy Tuesday. It is also not proof that the medicine “stopped working” in the pharmacological sense. In the trials, average weight fell for many months and then the curve flattened while people were still taking the drug. That shape is compatible with a real biological response and with a frustrating bathroom scale. This note is about how to think about a stall with your prescriber. It is not a protocol for raising your own dose.

What the trial curves actually did

In STEP 1, adults without diabetes received semaglutide 2.4 mg or placebo, plus lifestyle intervention, for 68 weeks. The mean weight change was −14.9 percent with semaglutide and −2.4 percent with placebo. The paper’s figure of weight over time is not a straight line that falls forever. The largest separation is visible well before week 68, and the mean is still a mean. Some participants lost much more, some much less. Half of the semaglutide group in that trial lost at least 15 percent. That implies half did not.

SURMOUNT-1 followed adults without diabetes for 72 weeks on tirzepatide 5, 10, or 15 mg or placebo, including a 20-week escalation. Mean weight change was −15.0 percent, −19.5 percent, and −20.9 percent across those three doses, versus −3.1 percent with placebo. Higher labeled doses produced larger average losses in that trial. That fact is not an instruction to jump to 15 mg because week 20 feels slow. The escalation inside the trial still took months, and adverse events were a reason some people stopped.

STEP 4 is the cleaner picture of “what if we change course mid-stream.” Adults completed a 20-week run-in on semaglutide, with a mean loss of about 10.6 percent, and then either continued the drug or switched to placebo for 48 weeks, with lifestyle support continuing. From week 20 to week 68, the continued-drug group lost about another 7.9 percent and the placebo group regained about 6.9 percent. The curve can still move after a person thinks they have stalled, and it can reverse if the drug is withdrawn. A four-week flat line is not STEP 4. It is a reason to look at dose, intake, and follow-up, which is the rest of this note.

Check the dose you are actually taking

Many stalls happen on a dose that was never the maintenance dose. Wegovy injection’s adult weight-reduction maintenance is 1.7 mg or, preferably in the label’s wording, 2.4 mg, reached only after the four-week steps through 0.25, 0.5, 1, and 1.7 mg. A further increase to 7.2 mg is allowed only if 2.4 mg has been tolerated for at least four weeks and additional weight reduction is clinically indicated. That sentence is doing a lot of work. “Clinically indicated” is the prescriber’s judgment. It is not a friend’s result.

Zepbound’s maintenance options for weight reduction are 5, 10, or 15 mg. The 2.5 mg dose is not a maintenance dose. If you have been on 5 mg for a long time because higher doses caused vomiting, staying there can be the right call even if the average in SURMOUNT-1 was larger at 15 mg. The label says to consider tolerability when the maintenance dose is chosen, and to consider a lower maintenance dose if a higher one is not tolerated. Trading a tolerable 5 mg for a 15 mg you cannot eat on is not automatically a better medical plan.

Missed doses and partial doses matter. If pens were skipped for travel or cost, you may not be on the pharmacology you think you are on. The missed-dose rules are in the first twelve weeks note and, more importantly, in the medication guide. Tell the prescriber the truth about missed weeks. A restart at a lower dose is sometimes what the label recommends after consecutive missed injections, precisely so gastrointestinal effects do not return in force.

Look at intake, protein, sleep, and the scale’s time frame

NIDDK’s eating guidance is still the right backdrop: a pattern built from vegetables, fruit, whole grains, protein foods, and dairy, with limits on added sugar, saturated fat, and sodium, plus at least 150 minutes a week of moderate activity and muscle-strengthening on two or more days, which is also what the Physical Activity Guidelines describe. On a GLP-1 medicine the failure mode is often under-eating protein and over-relying on small, refined snacks, or the opposite, a return of larger high-calorie meals once nausea fades. Neither one requires a new branded diet. A week of honest notes, portions as they were, is more useful to a clinician than a resolution to “be stricter.”

Sleep and alcohol change appetite and water weight. A salty weekend moves the scale without being a metabolic crisis. Weighing daily and looking at the weekly average, or weighing once a week under similar conditions, keeps a plateau from being declared on a bad morning. Strength training will not melt a stall by Friday. It is still the tool the activity guidelines give you for keeping muscle while weight is down. The eating note has the protein commentary from the clinical literature. Use it as a question for a dietitian if your intake is clearly low.

What not to do on your own

Do not stack a second GLP-1 product. Labels say concomitant use with another GLP-1 receptor agonist is not recommended. Do not use a compounded higher concentration because a message board said the approved maximum is timid. FDA has warned about compounded doses and titration schedules that go beyond the approved label, and about harm from dosing errors. Do not start a very low calorie diet to “break” a stall without supervision. Dehydration and gallbladder disease are already labeled concerns during weight loss.

Do not stop the drug for two weeks to “reset receptors.” STEP 4 is the evidence that stopping tends to move weight the other way. A supervised pause for surgery or for a severe side effect is a different decision, made with the clinicians who know why the pause is happening. The maintenance note covers stopping when stopping is the actual plan.

The follow-up conversation

Bring the dose, the missed doses, a rough intake picture, and the side effects you are willing or not willing to live with. Ask whether a labeled step up is available and wise, whether a condition such as an underactive thyroid or a new medicine explains the stall, and whether the goal has quietly shifted from more loss to keeping what you lost. For some people the plateau is the success, and chasing the trial’s top quartile is how side effects get invited back.

Give a stall a defined window before you rename it. Two weeks of no change, with a salty meal and a new strength workout in the middle, is not the shape of the STEP 1 curve. Six to eight weeks at a true maintenance dose, with doses actually taken, is a fair moment to ask whether the labeled options have been used. Write the weekly averages down so the conversation is about a trend. Mention constipation and fluid shifts, because a pound of either one can disguise a slower loss of body fat. Mention any new medicine, including steroids, some antidepressants, and insulin dose increases, which can move weight for reasons that have nothing to do with “willpower” and everything to do with the rest of the chart.

If you do not have a prescriber you can book for that conversation, the gap is the care, not the willpower. One telehealth practice that sees people for this kind of follow-up is described at read how SurpassMD describes a visit. A visit there, or with your own clinician, is the setting for a dose change. This note is not.

Sources we used

  1. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. https://pubmed.ncbi.nlm.nih.gov/35658024/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC7988425/
  4. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
  6. https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/eating-physical-activity
  7. https://odphp.health.gov/our-work/nutrition-physical-activity/physical-activity-guidelines/current-guidelines